A Phase 2 interventional study of REGEND001 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Regend Therapeutics. Completed at 4 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Regend Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.
Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 49th largest by enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2023, is one of 21 in phase 2, and was the 31st registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:
InSilico Medicine Hong Kong Limited · Sites in China
Ages 40+
AstraZeneca · Sites in China, United States, Argentina and 20 more countries
Ages 40+
Dragonboat Biopharmaceutical Company Limited · Sites in China
Ages 40+
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine · Sites in China
Ages 40–85
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 24 · Phase 3 14
First in 2012; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 83 across the 60 interventional studies, 310 across the 7 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 67 have an industry lead sponsor. The 10 most frequent:
Regend Therapeutics is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Regend Therapeutics has 3 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Idiopathic Pulmonary Fibrosis with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06125327Phase 3Guangzhou JOYO Pharma Co., LtdSC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | 2026-12-31 |
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT06267183Shanghai Synvida Biotechnology Co.,Ltd.A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. | 2026-11-30 |
| NCT07820254Shanghai Pulmonary Hospital, Shanghai, ChinaInspiratory Flow Rate Capability in Pulmonary Fibrosis Patients | 2026-12-31 |
| NCT07121413Shanghai Synvida Biotechnology Co.,Ltd.A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment. This is a multi-center, randomized, double-blinded, parallel and placebo-controlled phase II clinical study to evaluate the efficacy and safety of REGEND001 in IPF patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: REGEND001
Biological: Placebo
REGEND001: 1-1.5×10\^6 bronchial basal cells/kg administrated by bronchoscopy.
Placebo: Sodium chloride injection administrated by bronchoscopy.
Comparison of the area under the curve (AUC) of DLCO measured values at each visit from baseline to week 24 between the REGEND001 group and the placebo group.
DLCO is measured by the single-breath method. Improvement is defined as an increase in DLCO from baseline.
Time frame: 12 and 24 weeks after treatment
Change from baseline in lung diffusing capacity
DLCO will be used to evaluate the lung diffusing capacity. DLCO test refers to the diffusing capacity for carbon monoxide in the lungs. It's a type of pulmonary function test that helps to assess how well gas is exchanged between the lungs and the bloodstream.
Time frame: 12 and 24 weeks after treatment
Change from baseline in lung ventilatory capacity
Forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) will be used to evaluate the lung ventilatory capacity. FVC indicates the volume of air that can forcibly be blown out after full inspiration. FEV1 is the volume of breath exhaled with effort in one second.
Time frame: 12 and 24 weeks after treatment
Progression-free survival (PFS)
PFS refers to the time from randomization or initiation of treatment to the occurrence of disease progression or death.
Time frame: Within 24 weeks after treatment
Change from baseline in St. George's respiratory questionnaire (SGRQ) scale
Quality of life was assessed by St. George's respiratory questionnaire (SGRQ) scale. Total score, ranged from 0 to 100, is the sum of points from all items. A higher value represents a worse outcome.
Time frame: 12 and 24 weeks after treatment
Change from baseline in 6-minute-walk test (6MWT)
The 6MWT is a commonly used test for the objective assessment of functional exercise capacity by testing the distance patients can walk at the fastest speed within 6 minutes.
Time frame: 12 and 24 weeks after treatment
Time from enrollment to all-cause death
Time from enrollment to all-cause death is used to evaluate the overall survival of the population.
Time frame: up to 24 weeks(first period), 5 years (second period).
Blood oxygen saturation
Blood oxygen saturation is the measure of how much oxygen is traveling through body in red blood cells.
Time frame: 12 and 24 weeks after treatment
Change from baseline in images of lung by high resolution computed tomography (HR-CT)
HR-CT images of lung will be analyzed to indicate the change of pulmonary structure.
Time frame: 12 and 24 weeks after treatment
Change from baseline in C-reactive protein (CRP)
The level of CRP increases when there's inflammation in the body.
Time frame: 12 and 24 weeks after treatment
Time to acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF)
AE-IPF is an often deadly complication of IPF, which is defined as an acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality.
Time frame: Within 24 weeks after treatment
Temperature
Number of cases with abnormal body temperature.
Time frame: Within 24 weeks after treatment
Breathing
Number of cases with abnormal breathing.
Time frame: Within 24 weeks after treatment
Pulse
Number of cases with abnormal pulse.
Time frame: Within 24 weeks after treatment
Blood pressure
Number of cases with abnormal blood pressure.
Time frame: Within 24 weeks after treatment
Symptoms, physical examination
Number of cases with abnormal physical examination
Time frame: Within 24 weeks after treatment
12-lead ECG
Number of cases with abnormal 12-lead Electrocardiogram (ECG).
Time frame: Within 24 weeks after treatment
Blood routine
Number of cases with abnormal laboratory test results
Time frame: Within 24 weeks after treatment
Liver & Kidney function check
Number of cases with abnormal results in Liver \& Kidney function check
Time frame: Within 24 weeks after treatment
Blood glucose
Number of cases with abnormal results
Time frame: Within 24 weeks after treatment
Function of blood clotting
Number of cases with abnormal function of blood clotting.
Time frame: Within 24 weeks after treatment
Antibody testing for autoimmune diseases
Antibodies related to autoimmune diseases are tested for safety assessment
Time frame: Within 24 weeks after treatment
Carcinoembryonic antigen (CEA)
CEA is a tumor marker used for early diagnosis of lung cancer.Clinically significant changes of this markers will be assessed.
Time frame: Within 24 weeks after treatment
Neuron-specific enolase (NSE)
NSE is a tumor marker significantly elevated in small cell lung cancer. Clinically significant changes of this marker will be assessed
Time frame: Within 24 weeks after treatment
Cytokeratin-19-fragment (CYFRA21-1)
CYFRA21-1 is a tumor marker which is valuable for the pathological classification and prognosis evaluation of lung cancer. Clinically significant changes of this marker will be assessed
Time frame: Within 24 weeks after treatment
Squamous cell carcinoma antigen (SCC)
SCC is a specific marker for lung squamous cell carcinoma. Clinically significant changes of this marker will be assessed
Time frame: Within 24 weeks after treatment
Other cases of adverse effects
Other cases of adverse effects will be recorded and compared.
Time frame: Within 24 weeks after treatment
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in Mar 2025, 15 months.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 15 months is below that.
Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: REGEND001
Idiopathic Pulmonary Fibrosis →
Regend Therapeutics